References
- 1. Chabner BA. General principles of cancer chemotherapy. In: Brunton L, Chabner B, Knollmman B, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw Hill Medical. 2011;60:1667-75.
- 2. Romond EH, Perez EA, Bryant J. Transtuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.10.1056/NEJMoa052122
- 3. Batchelor TA, Sorensen AG, Di Tomaso E. AZD2171, a pan-VAGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:3-95.10.1016/j.ccr.2006.11.021
- 4. Holleman A, Den Boer ML, De Menezes RX. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood lymphoblastic leukemia. Blood. 2006;107:769-76.10.1182/blood-2005-07-2930
- 5. Preusser M, De Mattos-Arrude L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, De Azambuja E, Zielinski CC. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open. 2018;3:1-19.10.1136/esmoopen-2018-000368
- 6. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417-30.10.1038/nrclinonc.2016.26
- 7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.10.1016/j.cell.2011.02.013
- 8. Chabner BA, Bertini J, Cleary J, Ortiz T, Lane A, Surko JG, Ruan D. Cytotoxic agents. In: Brunton L, Chabner B, Knollmman B, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw Hill Medical. 2011;62:1677-730.
- 9. Thummel KE, Shen DD, Isoherranen N. Design and optimization of dosage regiments: Pharmacokinetic data. In: Brunton L, Chabner B, Knollmman B, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw Hill Medical. 2011;62:1891-990.
- 10. De Gramont A, Louvet C, Andre T. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: Evolution of regimen. Groupe d’Etude et de Recherche sur les Cancers de l’Ovarie et Degestifs (GERCOD). Eur J Cancer. 1998;34:619-26.10.1016/S0959-8049(97)00364-X
- 11. Petrelli F, Cabiddu M, Barni S. 5-Fluorouracil or Capecitabine in the treatment of advanced colorectal cancer: a pooled analysis of randomized trials. Med.Oncol. 2012;29:1020-9.10.1007/s12032-011-9958-0
- 12. European Medicine Agency. Updated Joint Assessment Report. EMA. 2019:November 22.
- 13. Lee C, Ryan EJ, Doherty GA. Gastrointestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. J Gastroenterol. 2014;20:3751-61.10.3748/wjg.v20.i14.3751
- 14. Wilhelm M, Mueller L, Miller MC. Prospective, multicenter study of 5-Fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin Colorect Cancer. 2016;15:381-8.10.1016/j.clcc.2016.04.00127256667
- 15. Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. 5-Fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19:453-8.10.5603/CJ.2012.0084
- 16. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity on cancer patients treated with5-fluorouracil or capecitabine: a systemic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974-84.10.1016/j.ctrv.2013.03.00523582737
- 17. Twelves C, Glynne-Jones R, Cassidy J. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999;5:1696-702.
- 18. Kemeny N, Huang Y, Cohen MA. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039-48.10.1056/NEJM199912303412702
- 19. Bennett JE. Antifungal agents. In: Brunton L, Chabner B, Knollmman B, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw Hill Medical. 2011;60:1571-91.
- 20. Diasio RB, Beavers T., Carpenter JT. Potential importance of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil induced toxicity. J Clin Invest. 1988;81:47-51.10.1172/JCI113308
- 21. Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics. 1994;4:301-6.10.1097/00008571-199412000-00002
- 22. Gonzelez FJ, Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci. 1995;16:325-7.10.1016/S0165-6147(00)89065-3
- 23. Meulendijks D, Henricks LM, Sonke GS. Clinical toxicity relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.601G>A a predictors of severe fluoropyrimdine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:1639-50.10.1016/S1470-2045(15)00286-7
- 24. Van Kuilenburg AB, Haasjes J, Richel DJ. Clinical implications of dihydopyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-12.
- 25. Terrazzino S, Cargnin S, Del Re M. DPDY IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta analysis. Pharmacogenomics. 2013;14:1255-72.10.2217/pgs.13.11623930673
- 26. Froelich TK, Amstitz U, Aebi S. Clinical importance of risk variants in the dihydopyrimidine dehydrogenase gene for the precision of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136:730-9.10.1002/ijc.29025
- 27. Mercier, C., Ciccolini, J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-Fluoroueacil / Capecitabine therapy. Clin. Colorectal Cancer. 2006; 6:288-96.10.3816/CCC.2006.n.04717241513
- 28. Leung WC, Chan ALF. Association and prediction of severe 5-fluorouacil toxicity with dihydropyrimidine dehydrogenase gene polymorphism: A meta-analysis. Biomed Reports. 2015;3:879-83.10.3892/br.2015.513466058626623034
- 29. Deenen MJ, Meulendijks D, Cats A. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: A safety and cost analysis. Clin Oncol. 2016;34:227-34.10.1200/JCO.2015.63.132526573078
- 30. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schillens JHM, Swen JJ, Klei TE, McLeod HL, Klaude KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidene Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103:210-6.10.1002/cpt.911576039729152729
- 31. Institut national du Cancer. DPD deficiency screening with a view to preventing some severe toxicities occurring with treatments including fluoropyrimidines (5-fluorouracil or capecitabine). INCA, December 2018.
- 32. Zhang X, Li L, Fourie J, Davie J, Guarcello V, Diasio R. The role of SP1 and SP3 in the constitutive DPYD gene expression. Biochem Biophys Acta. 2006;175:247-56.10.1016/j.bbaexp.2006.05.00116806531
- 33. Loganayagam A, Arenas-Hernandez M, Corrigan A. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013;108:2505-15.10.1038/bjc.2013.262369424323736036
- 34. Rosmarin D, Palles C, Pagnamenta A. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at PY and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64:111-20.10.1136/gutjnl-2013-306571428362224647007
- 35. Ezzeldin H, Lee A, Mattison L, Diasio R. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 2005;11: 8699-705.10.1158/1078-0432.CCR-05-152016361556
- 36. Harris B, Song R, Soong S, Diasio R. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma levels in cancer patients receiving 5-Flourouracil by protracted continuous infusion. Cancer Res. 1990;50:197-201.
- 37. Jacobs BA, Deenen MJ, Plum D. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol. 2016;82:706-16.10.1111/bcp.13007533810127161955
- 38. Loriot MA, Ciccoline J, Thomas F, Barin Le Guellec C, Royer F, Milano J, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hannart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC. Dihydropyrimidine dehydrogenase (DPD) deficiency screening and fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer. 2018;105:397-407.10.1016/j.bulcan.2018.02.00129486921
- 39. Sistonen J, Buchel B, Froehlic TK, Kummer D, Fontana S, Joerger M. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil : uracil ratio. Pharmacogenomics. 2014;15:1653-66.10.2217/pgs.14.12625410891
- 40. Lunenburg C, Henrocks LM, Guchelaar HJ. Prospectieve DPYD genotyping to reduce the risk of fluoropyrimidine-indiced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40-8.10.1016/j.ejca.2015.11.00826716401
- 41. Van Kuilenburg A, Meijer J, Tanck MW, Dobritzsch D, Zoetekouw L, Dekkers, LL. Phenotyping and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochem Biophys Acta. 2016;186:754-62.10.1016/j.bbadis.2016.01.009
- 42. Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, De Vries N, Rosing H, Van Werkhoven E, De Boer A, Beijnen JH, Mandigers C, Soesan M, Cats A, Schellens JHM. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116:1415-24.10.1038/bjc.2017.94552009928427087
- 43. Ciccolini J, Del Re M, Danesi R. Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTS position. Ann Oncology. 2018;29:1893-94.10.1093/annonc/mdy25830032203
- 44. Boisdron-Celle M, Capitain O, Faroux R. Prevention of 5-fluorouracil-induced early severe toxicity by pretherapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of multiparametric approach. Semin Oncology. 2017;44:13-23.10.1053/j.seminoncol.2017.02.00828395758
- 45. Beumer JH, Chu E, Allegra C, Tanigawara Y, Nilano G, Diasio R, Kim TW, Mathjissen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joergr M. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther. 2019;105: 598-613.10.1002/cpt.1124630928629923599
- 46. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899-902.
- 47. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993;53:5433-8.